Highlights from ASCO
June 5, 2023
Dr Claudio Cerchione summarised the educational session on the management of multiple myeloma in special patient populations, such as elderly and patients with renal failure.
From 2 June till 6 June 2023: HIGHLIGHTS FROM ASCO
Your direct line with Chicago
The American Society of Clinical Oncology (ASCO) 2023 brings together leading experts in the different fields of cancer from around the world. And, as usual, they gather together in Chicago, USA. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
With the support of:
Daily highlights
Project in the spotlight
Updates from GMMG-HD7
December 19, 2024
In this video, Dr Elias Mai, haematologist at the Heidelberg University Hospital in Germany and one of the lead investigator of GMMG-HD7, shares the key take-aways of these abstracts.
Five-year follow-up of the phase II OPTIC study
December 19, 2024
In this video, Prof Jorge Cortes, haematologist at the Georgia Cancer Centre in Augusta, Georgia (USA), discusses the 5-year follow up data of this trial presented at ASH 2024.
Frontline ponatinib plus blinatumomab for Ph+ ALL
December 18, 2024
In this video, Prof Robin Foà, emeritus professor of haematology at the Sapienza University of Rome discusses two abstracts presented at ASH zooming in on the use of ponatinib plus
Updates from the EAE115 and IONA-MM studies
December 18, 2024
In this video, Prof Fredrik Schjesvold, head of the Oslo myeloma center in Oslo (Norway), discusses the results of the EAE 115 study evaluating this regimen as a second line
MRD negativity dynamics in the IMROZ study
December 16, 2024
Dr Robert Orlowski, a haematologist at the University of Texas MD Anderson Cancer Center in Houston, Texas, provided a comprehensive summary of his presentation on MRD testing in the context
inMIND study in R/R follicular lymphoma
December 13, 2024
Prof Marek Trneny, haematologist at Charles University General Hospital in Prague, Czech Republic, presented findings from the inMIND study, featured as a late-breaking abstract at the ASH meeting.
DREAMM-7 study in R/R MM
December 13, 2024
Prof Dr Claudio Cerchione, a haematologist at the Istituto Romagnolo per lo Studio dei Tumori in Meldola, Italy, co-authored the DREAMM-7 study and shared updated efficacy data presented at ASH
AALL1731 trial
December 12, 2024
Dr Sumit Gupta, a paediatric oncologist and assistant professor at the Hospital for Sick Children and the University of Toronto, Canada, presented the main findings of the AALL1731 study, of
In-depth stories
Updates from GMMG-HD7
December 19, 2024
In this video, Dr Elias Mai, haematologist at the Heidelberg University Hospital in Germany and one of the lead investigator of GMMG-HD7, shares the key take-aways of these abstracts.
Five-year follow-up of the phase II OPTIC study
December 19, 2024
In this video, Prof Jorge Cortes, haematologist at the Georgia Cancer Centre in Augusta, Georgia (USA), discusses the 5-year follow up data of this trial presented at ASH 2024.
Frontline ponatinib plus blinatumomab for Ph+ ALL
December 18, 2024
In this video, Prof Robin Foà, emeritus professor of haematology at the Sapienza University of Rome discusses two abstracts presented at ASH zooming in on the use of ponatinib plus
Updates from the EAE115 and IONA-MM studies
December 18, 2024
In this video, Prof Fredrik Schjesvold, head of the Oslo myeloma center in Oslo (Norway), discusses the results of the EAE 115 study evaluating this regimen as a second line
MRD negativity dynamics in the IMROZ study
December 16, 2024
Dr Robert Orlowski, a haematologist at the University of Texas MD Anderson Cancer Center in Houston, Texas, provided a comprehensive summary of his presentation on MRD testing in the context
inMIND study in R/R follicular lymphoma
December 13, 2024
Prof Marek Trneny, haematologist at Charles University General Hospital in Prague, Czech Republic, presented findings from the inMIND study, featured as a late-breaking abstract at the ASH meeting.
DREAMM-7 study in R/R MM
December 13, 2024
Prof Dr Claudio Cerchione, a haematologist at the Istituto Romagnolo per lo Studio dei Tumori in Meldola, Italy, co-authored the DREAMM-7 study and shared updated efficacy data presented at ASH
AALL1731 trial
December 12, 2024
Dr Sumit Gupta, a paediatric oncologist and assistant professor at the Hospital for Sick Children and the University of Toronto, Canada, presented the main findings of the AALL1731 study, of
Poster selection
Transfusion practice for sickle cell disease in a Belgian reference centre
July 17, 2024
Dr Yvan Momo, a haematologist at the Hopital Universitaire de Bruxelles in Brussels, presents an analysis of transfusion practices in a Belgian sickle cell reference centre, assessing their adherence to
Brentuximab vedotin + pembrolizumab in R/R cHL
July 17, 2024
The current standard treatment for R/R cHL involves salvage chemotherapy followed by ASCT. However, the optimal salvage therapy regimen remains undefined. Recent evidence suggests that the combination of brentuximab vedotin
Dual targeting of EZH2 and HDAC in haematological malignancies
July 17, 2024
Thomas Slegers, a doctoral researcher, and Dr Marlies Vanden Bempt, a postdoctoral researcher, both from KU Leuven, presented their research on the dual targeting of EZH2 and HDAC in haematological
The PREAMBLE registry
July 10, 2024
Prof Dr Claudio Cerchione, a haematologist at the Istituto Romagnolo per lo Studio dei Tumori in Meldola, Italy, shares insights from the PREAMBLE registry. This registry documents treatment patterns and
QuANTUM-First: Efficacy by age in newly diagnosed FLT3-ITD–positive AML
July 1, 2024
Dr Pau Montesinos, a haematologist at the Hospital Universitario y Politècnico La Fe in Valencia, Spain, presented a post hoc analysis of the phase 3 QuANTUM-First study. This analysis evaluated
The Impact of Isatuximab HGG in R/R MM patients
December 13, 2023
Dr Cesar Rodriguez, affiliated with Mount Sinai in New York, presents a research study examining the impact of isatuximab (Isa) on the occurrence of hypogammaglobulinemia (HGG) and the concomitant risk
AML real world evidence initiative: venetoclax versus control in patients unfit for intensive chemotherapy
December 13, 2023
In this study, Dr Aaron Goldberg from the Memorial Sloan Kettering Cancer Center presents a comparative analysis of outcomes and healthcare research utilization in patients with AML treated with venetoclax
ELEVATE-TN: Impact of first-year dose modifications in treatment-naive CLL patients treated with acalabrutinib
December 13, 2023
Prof George Follows, a consulting haematologist from Nuffield Health Cambridge Hospital, presents a post-hoc analysis of the ELEVATE-TN trial, a prospective, randomized study involving treatment-naïve elderly CLL patients. Patients were